Becker's Healthcare September 3, 2024
Elizabeth Gregerson

Swiss pharmaceutical company Sandoz is launching a generic semaglutide, the main ingredient of Ozempic, in the U.S. when the market opens in 2030, Bloomberg reported Sept. 3.

The company first plans to launch the generic, which is approved for Type 2 diabetes (Ozempic) and weight loss (Wegovy), in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More

Share This Article